Review

cd38 apc (Miltenyi Biotec)

Miltenyi Biotec is a verified supplier

Miltenyi Biotec manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Miltenyi Biotec cd38 apc
Cd38 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd38+apc/pm41776652-101-23-27?v=Miltenyi+Biotec
Average 95 stars, based on 3 article reviews

cd38 apc - by Bioz Stars, 2026-08

95/100 stars

Images

Image Search Results

ALDH1A1 increased after conventional chemotherapy regimen Vrd or Krd. A and B. GSE276561 and GSE47552 datasets revealed ALDH1A1 in MM was lower than healthy control; These GEO data were analyzed by on line tool GEO2R using Benjamini & Hochberg (False discovery rate) method; Each y axis label in the graph represents the expression measurement extracted from the TPM normalized expression counts (for RNA-seq), or the Value column of the original submitter-supplied Sample record (for microarrays). All the y axis label represents normalized mRNA expression level. C. mRNA levels of ALDH1A1 in NDMM samples are significantly lower than healthy control, but remarkably higher in RRMM samples than NDMM patients which are collected in our hospital; Relative ALDH1A1 levels is relative to GAPDH. D. mRNA levels of CD38 in NDMM patients are significantly higher than healthy control which are collected in our hospital; Relative CD38 levels is relative to GAPDH. E. ALDH1A1 mRNA increased after Vrd or Krd treatment; Relative ALDH1A1 levels is relative to GAPDH. F . western blot confirmed ALDH1A1 protein increased after Vrd or Krd treatment. **, p < 0.01, ***, p < 0.001. C-E, Data was analyzed by Mann-Whitnay test HC: healthy control; Vrd: Bortezomib + Lenalidomide + Dexamethasone; KRd: Carfilzomib + Lenalidomide + Dexamethasone; MM: multiple myeloma; NDMM: newly diagnosed multiple myeloma; SMM: smoldering multiple myeloma; MGUS: monoclonal gammopathy of undetermined significance

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Reduced ALDH1A1 expression in multiple myeloma cells increases resistance to daratumumab via downregulation of retinoic acid

doi: 10.1007/s00018-025-05891-7

Figure Lengend Snippet: ALDH1A1 increased after conventional chemotherapy regimen Vrd or Krd. A and B. GSE276561 and GSE47552 datasets revealed ALDH1A1 in MM was lower than healthy control; These GEO data were analyzed by on line tool GEO2R using Benjamini & Hochberg (False discovery rate) method; Each y axis label in the graph represents the expression measurement extracted from the TPM normalized expression counts (for RNA-seq), or the Value column of the original submitter-supplied Sample record (for microarrays). All the y axis label represents normalized mRNA expression level. C. mRNA levels of ALDH1A1 in NDMM samples are significantly lower than healthy control, but remarkably higher in RRMM samples than NDMM patients which are collected in our hospital; Relative ALDH1A1 levels is relative to GAPDH. D. mRNA levels of CD38 in NDMM patients are significantly higher than healthy control which are collected in our hospital; Relative CD38 levels is relative to GAPDH. E. ALDH1A1 mRNA increased after Vrd or Krd treatment; Relative ALDH1A1 levels is relative to GAPDH. F . western blot confirmed ALDH1A1 protein increased after Vrd or Krd treatment. **, p < 0.01, ***, p < 0.001. C-E, Data was analyzed by Mann-Whitnay test HC: healthy control; Vrd: Bortezomib + Lenalidomide + Dexamethasone; KRd: Carfilzomib + Lenalidomide + Dexamethasone; MM: multiple myeloma; NDMM: newly diagnosed multiple myeloma; SMM: smoldering multiple myeloma; MGUS: monoclonal gammopathy of undetermined significance

Article Snippet: The positive CD38 cells were labeled by APC anti-human CD38 antibody (E-AB-F1058E, Elabscience) or APC anti-mouse CD38 antibody (E-AB-F1193E, Elabscience) and analyzed by FACSCantoTM II flow cytometer.

Techniques: Control, Expressing, RNA Sequencing, Western Blot

$ALDH1A1 down-regulated in the nrRRMM patients received Dara-Rd treatment. A and B. rRRMM patients had higher ALDH1A expression compared with nrRRMM after Dara-Rd treatment analyzed by RT-qPCR and western blot; C and D . the CD38 expression (mRNA and protein) decreased in Dara-treated patients in nrRRMM patients compared with rRRMM patients; E . the mRNA expression of ALDH1A1 after Dara-based treatment was positively correlated with the CD38 mRNA expression. **, p < 0.01 A-D, data was analyzed by student t test. E, data was analyzed by simple linear regression nrRRMM: non-responder relapsed/refractory multiple myeloma; rRRMM: responder relapsed/refractory multiple myeloma; MFI: median fluorescence intensity; Dara-Rd: daratumumab + lenalidomide + dexamethasone; Dara: daratumumab$

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Reduced ALDH1A1 expression in multiple myeloma cells increases resistance to daratumumab via downregulation of retinoic acid

doi: 10.1007/s00018-025-05891-7

Figure Lengend Snippet: ALDH1A1 down-regulated in the nrRRMM patients received Dara-Rd treatment. A and B. rRRMM patients had higher ALDH1A expression compared with nrRRMM after Dara-Rd treatment analyzed by RT-qPCR and western blot; C and D . the CD38 expression (mRNA and protein) decreased in Dara-treated patients in nrRRMM patients compared with rRRMM patients; E . the mRNA expression of ALDH1A1 after Dara-based treatment was positively correlated with the CD38 mRNA expression. **, p < 0.01 A-D, data was analyzed by student t test. E, data was analyzed by simple linear regression nrRRMM: non-responder relapsed/refractory multiple myeloma; rRRMM: responder relapsed/refractory multiple myeloma; MFI: median fluorescence intensity; Dara-Rd: daratumumab + lenalidomide + dexamethasone; Dara: daratumumab

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Fluorescence

ALDH1A1 directly regulates CD38 expression in H929 cells. A . the KD efficiency of different sh-ALDH1A1 sequences; B . Knock down ALDH1A1 decreased CD38 genes expression; C. Re-introducing ALDH1A1-OE plasmid restored downregulation of ALDH1A1 mRNA levels in ALDH1A1-KD cells; D . Re-introducing ALDH1A1 into ALDH1A1-KD cells significantly upregulate the expression of CD38; E . cell-surface expression of CD38 decreased in ALDH1A1-KD cells but restored by re-introducing ALDH1A1-OE plasmid determined by flow cytometry analysis. **, p < 0.01, ***, p < 0.001 Student t test was performed in all datasets AlDH1A1-KD: ALDH1A1 knockdown; Ctrl: control; shALDH1A1: short hairpin RNA for ALDH1A1; KD-OE: over expression of ALDH1A1 in KD cells

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Reduced ALDH1A1 expression in multiple myeloma cells increases resistance to daratumumab via downregulation of retinoic acid

doi: 10.1007/s00018-025-05891-7

Figure Lengend Snippet: ALDH1A1 directly regulates CD38 expression in H929 cells. A . the KD efficiency of different sh-ALDH1A1 sequences; B . Knock down ALDH1A1 decreased CD38 genes expression; C. Re-introducing ALDH1A1-OE plasmid restored downregulation of ALDH1A1 mRNA levels in ALDH1A1-KD cells; D . Re-introducing ALDH1A1 into ALDH1A1-KD cells significantly upregulate the expression of CD38; E . cell-surface expression of CD38 decreased in ALDH1A1-KD cells but restored by re-introducing ALDH1A1-OE plasmid determined by flow cytometry analysis. **, p < 0.01, ***, p < 0.001 Student t test was performed in all datasets AlDH1A1-KD: ALDH1A1 knockdown; Ctrl: control; shALDH1A1: short hairpin RNA for ALDH1A1; KD-OE: over expression of ALDH1A1 in KD cells

Techniques: Expressing, Knockdown, Plasmid Preparation, Flow Cytometry, Control, shRNA, Over Expression

ALDH1A1 increased CD38 through activation of RA/RAR via RA production. A . Volcano plots created by differential mRNA (fold change (FC) > 2 or < 0.5, and p < 0.05); B. KEGG analysis in ALDH1A1 KD cells of H929 and 8226 cells revealed that retinoic acid receptor, and retinoid X receptor agonists/antagonists pathways were enriched in both cell line; C. Knock down ALDH1A1caused downregulation of RAR proteins while re-introduced ALDH1A1 into ALDH1A1-KD cells increased their expressions; D . RA salvage restore the ADCC of Dara against MM cells; E . the RAR protein level was significantly increased determined by western blot after RA supplement; (F) mRNA levels of CD38 determined by RT-qPCR; (G) protein levels of CD38 determined by western blot. **, p < 0.01, ***, p < 0.001 C-G, student t test was adopted KD: ALDH1A1 knockdown; Ctrl: control; KD-OE: over expression of ALDH1A1 in KD cells; RA: retinoic acid; RAR: retinoic acid receptor; ADCC: antibody-dependent cellular cytotoxicity

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Reduced ALDH1A1 expression in multiple myeloma cells increases resistance to daratumumab via downregulation of retinoic acid

doi: 10.1007/s00018-025-05891-7

Figure Lengend Snippet: ALDH1A1 increased CD38 through activation of RA/RAR via RA production. A . Volcano plots created by differential mRNA (fold change (FC) > 2 or < 0.5, and p < 0.05); B. KEGG analysis in ALDH1A1 KD cells of H929 and 8226 cells revealed that retinoic acid receptor, and retinoid X receptor agonists/antagonists pathways were enriched in both cell line; C. Knock down ALDH1A1caused downregulation of RAR proteins while re-introduced ALDH1A1 into ALDH1A1-KD cells increased their expressions; D . RA salvage restore the ADCC of Dara against MM cells; E . the RAR protein level was significantly increased determined by western blot after RA supplement; (F) mRNA levels of CD38 determined by RT-qPCR; (G) protein levels of CD38 determined by western blot. **, p < 0.01, ***, p < 0.001 C-G, student t test was adopted KD: ALDH1A1 knockdown; Ctrl: control; KD-OE: over expression of ALDH1A1 in KD cells; RA: retinoic acid; RAR: retinoic acid receptor; ADCC: antibody-dependent cellular cytotoxicity

Techniques: Activation Assay, Knockdown, Western Blot, Quantitative RT-PCR, Control, Over Expression

ALDH1A1 inhibitor reduces the sensitivity of Dara in vivo through inhibiting the RA/RAR pathway. A and B . compared with vehicle control, Dara cause significantly reduction of xenograft tumors weight and tumor growth; C . inhibitor of ALDH1A 673 A remarkably reduce the protein level of CD38, ALDH1A1 and RAR, and RA complement significantly restore the protein level of CD38 and RAR. *, p < 0.05, **, p < 0.01, ***, p < 0.001 A-B, analysis of variance (ANOVA) was used for multi-group comparisons followed by Tukey’s post hoc test ( N = 6); C, analysis of variance (ANOVA) was used for multi-group comparisons followed by Tukey’s post hoc test ( N = 3) RA: retinoic acid; RAR: retinoic acid receptor

Journal: Cellular and Molecular Life Sciences: CMLS

Article Title: Reduced ALDH1A1 expression in multiple myeloma cells increases resistance to daratumumab via downregulation of retinoic acid

doi: 10.1007/s00018-025-05891-7

Figure Lengend Snippet: ALDH1A1 inhibitor reduces the sensitivity of Dara in vivo through inhibiting the RA/RAR pathway. A and B . compared with vehicle control, Dara cause significantly reduction of xenograft tumors weight and tumor growth; C . inhibitor of ALDH1A 673 A remarkably reduce the protein level of CD38, ALDH1A1 and RAR, and RA complement significantly restore the protein level of CD38 and RAR. *, p < 0.05, **, p < 0.01, ***, p < 0.001 A-B, analysis of variance (ANOVA) was used for multi-group comparisons followed by Tukey’s post hoc test ( N = 6); C, analysis of variance (ANOVA) was used for multi-group comparisons followed by Tukey’s post hoc test ( N = 3) RA: retinoic acid; RAR: retinoic acid receptor

Techniques: In Vivo, Control

Review

Structured Review

Images

Similar Products

Image Search Results